DUSSELDORF, Germany, July 3 /PRNewswire/ --

- Through the joint venture, Gerresheimer expands its leading
position in the field of life science research.

- CEO Dr. Axel Herberg: "The joint venture is an important part of
Gerresheimer's growth strategy and allows both companies to profit from
market and production synergies."

- Kimble Chase Life Science and Research Products LLC had total
sales of around EUR100 million in 2006 (pro forma).

The formation of the joint venture was finalised yesterday. On
20 March 2007 Gerresheimer had already announced the establishment of the
joint venture with a subsidiary of Thermo Fisher Scientific Inc. (TMO) in 
the USA. The out-standing conditions, particularly approval by the antitrust
authorities, have now been fulfilled.

With a 51% share Gerresheimer has a majority interest in the
new company "Kimble Chase Life Science and Research Products LLC" (Kimble
Chase). TMO holds 49% of the shares. The joint venture specialises in the
development, production and marketing of life science products and employs
around 1,500 people in seven loca-tions. Gerresheimer contributes production
plants in the USA, Mexico and China and TMO production plants in the USA and
Germany. The company is based in New Jersey/USA. Its products are used in
industrial pharmaceutical research and are largely marketed under the
trademarks Kimble, Kontes and Bomex. In the financial year 2006, sales by
Kimble Chase totalled around EUR100 million (pro forma).

"The joint venture marks another important step by the
Gerresheimer Group on the way to becoming a global pharma & life science
group. In this way we will continue to pursue our growth strategy in the
future and offer our shareholders an attractive investment," says Dr. Axel
Herberg, CEO of Gerresheimer AG

With Kimble Chase the Gerresheimer Group employs around 10,000
people in 37 locations around the world and approaches a total sales level 
of EUR1 billion in 2007 as planned. Since 11 June 2007 Gerresheimer has been
listed in the Prime Standard of the Frankfurt stock exchange, following one
of the largest flotations of the year with a total issue volume of around
EUR1 billion.

Note to Editors

You can request photos on this topic via our homepage.
If required, we can also send you high-resolution data. Reprint free of
charge. Please send specimen copy to Gerresheimer.

(c) Gerresheimer

Contact:
    Burkhard Lingenberg
    Director Corporate PR & Marketing
    Phone +49-(0)211-6181-250
    b.lingenberg@gerresheimer.com



Gerresheimer is a pharmaceutical & life science supply and
services company with market leading positions of specialty products made 
of glass and plastic. Gerresheimer owns 37 production sites in Europe, North
America and Asia and employs approximately 10,000 employees worldwide.